# JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation

Source: https://onco.cc/trials/nct05194995/  
OnCo record `nct05194995` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Glecirasib, Cetuximab in colorectal cancer, run by Allist Pharmaceuticals, Inc., active and no longer recruiting.

## Summary

JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation is a phase 1/2 interventional study registered as NCT05194995 by Allist Pharmaceuticals, Inc., with 48 participants enrolled, started 2022-02-17 and due to reach its primary completion in 2025-04-30. Interventions recorded: JAB-21822, Cetuximab. Conditions listed: Advanced Colorectal Cancer, Small Intestinal Cancer, Appendiceal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05194995
- Phase: 1/2
- Setting: A Phase Ib/II Trial of JAB-21822 in Combination With Cetuximab in Patients With Advanced Colorectal Cancer, Small Intestine Cancer and Appendiceal Cancer With KRAS G12C Mutation
- Sponsor: Allist Pharmaceuticals, Inc.
- Enrolled: 48

## Sources

- ClinicalTrials.gov NCT05194995: https://clinicaltrials.gov/study/NCT05194995

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Cetuximab](https://onco.cc/drugs/cetuximab/), [Glecirasib](https://onco.cc/drugs/glecirasib/)
- companies: [Shanghai Allist Pharmaceuticals](https://onco.cc/companies/allist/)

---
JSON: https://onco.cc/api/v1/entities/nct05194995.json